The concern of generic challenges has long loomed around copyright’s blockbuster drug, Sildenafil, triggering questions about the future of similar pharmaceutical investments. While initial years saw significant returns, the patent end has opened the path for cheaper copies, likely lowering earnings and presenting a real risk for shareholders lo… Read More